SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Nastech (NSTK)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Kip518 who wrote (6)1/6/1997 8:06:00 AM
From: Kip518   of 25
 
News: DynaGen To License NicErase Nasal Spray To Nastech (DJ)

CAMBRIDGE, Mass. -- DynaGen Inc. (DYGN) licensed worldwide, exclusive
rights to develop NicErase-NS lobeline sulfate nasal delivery formulation to Nastech Pharmaceutical Co. (NSTK).

In a press release, DynaGen said Nastech will be responsible for the
development of nasal formulations, preclinical animal studies and limited human studies and will bear all the development costs.

DynaGen and Nastech will cooperate in licensing the product to a third party, and will share equally in licensing fees and in royalties.

DynaGen said NicErase-SL reduces symptoms of tobacco withdrawal. The
company is now evaluating its effectiveness as an aid in smoking cessation in a 750 subject multi-center pivotal Phase III trial.

Lobeline exhibits many of the pharmacological effects of nicotine, although it is considered to be non-habit forming.

Nastech Pharmaceutical, Hauppauge, N.Y., develops nasally delivered drugs for pharmaceuticals that are currently available in an oral and injectable dosage forms.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News